Journal of Experimental & Clinical Cancer Research,
Год журнала:
2022,
Номер
41(1)
Опубликована: Янв. 25, 2022
Glioblastoma
(GBM)
treatment
has
remained
almost
unchanged
for
more
than
20
years.
The
current
standard
of
care
involves
surgical
resection
(if
possible)
followed
by
concomitant
radiotherapy
and
chemotherapy.
In
recent
years,
immunotherapy
strategies
have
revolutionized
the
many
cancers,
increasing
hope
GBM
therapy.
However,
mostly
due
to
high,
multifactorial
immunosuppression
occurring
in
microenvironment,
poor
knowledge
neuroimmune
system
presence
blood-brain
barrier,
efficacy
is
still
low.
Recently,
new
treatments
employed
combinations
provided
encouraging
results
both
preclinical
clinical
studies.
lessons
learned
from
trials
highlight
importance
tackling
different
arms
immunity.
this
review,
we
aim
summarize
evidence
regarding
combination
terms
immune
survival
benefits
management.
outcomes
studies
assessing
classes
immunotherapeutic
agents
(e.g.,
checkpoint
blockade
vaccines)
will
be
discussed.
Finally,
future
ameliorate
facilitate
translation
address
unmet
medical
needs
GBM.
Science,
Год журнала:
2014,
Номер
344(6190), С. 1396 - 1401
Опубликована: Июнь 13, 2014
Human
cancers
are
complex
ecosystems
composed
of
cells
with
distinct
phenotypes,
genotypes,
and
epigenetic
states,
but
current
models
do
not
adequately
reflect
tumor
composition
in
patients.
We
used
single-cell
RNA
sequencing
(RNA-seq)
to
profile
430
from
five
primary
glioblastomas,
which
we
found
be
inherently
variable
their
expression
diverse
transcriptional
programs
related
oncogenic
signaling,
proliferation,
complement/immune
response,
hypoxia.
also
observed
a
continuum
stemness-related
states
that
enabled
us
identify
putative
regulators
stemness
vivo.
Finally,
show
established
glioblastoma
subtype
classifiers
variably
expressed
across
individual
within
demonstrate
the
potential
prognostic
implications
such
intratumoral
heterogeneity.
Thus,
reveal
previously
unappreciated
heterogeneity
regulatory
central
biology,
prognosis,
therapy.
Glioblastoma
multiforme
(GBM)
is
one
of
the
most
malignant
types
central
nervous
system
tumors.
Despite
advances
in
treatment
modalities
it
remains
largely
incurable.
The
objective
our
review
to
provide
a
holistic
picture
GBM
epidemiology,
etiology,
pathogenesis,
clinical
findings
and
treatment.
A
literature
search
was
conducted
for
at
PubMed
Google
Scholar,
with
relevant
key
words
like
glioblastoma
multiforme,
signs
symptoms,
etc.,
papers
published
until
2015
were
reviewed.
It
found
that
radiation
certain
genetic
syndromes
are
only
risk
factors
identified
date
GBM.
Depending
on
tumor
site
patients
may
present
clinic
varying
symptoms.
To
confirm
presence
extent
tumor,
various
invasive
non-invasive
imaging
techniques
require
employment.
survey
revealed
pathogenesis
involve
aberrations
multiple
signaling
pathways
through
mutations
altered
gene
expression.
Although
several
options
available,
including
surgery,
along
adjuvant
chemo-
radio-therapy,
disease
has
poor
prognosis
generally
succumb
within
14
months
diagnosis.
Journal of Clinical Oncology,
Год журнала:
2017,
Номер
35(21), С. 2402 - 2409
Опубликована: Июнь 22, 2017
Glioblastoma
(GBM)
is
a
rare
tumor
and
one
of
the
most
challenging
malignancies
to
treat
in
all
oncology.
Although
advances
have
been
made
treatment
GBM,
encouraging
outcomes
typically
are
not
observed;
patients
diagnosed
with
these
tumors
generally
dismal
prognosis
poor
quality
life
as
disease
progresses.
This
review
summarizes
clinical
presentation
diagnostic
methods,
evidentiary
basis
for
current
standards
care,
investigational
approaches
or
manage
GBM.
Because
track
record
developing
effective
therapies
GBM
has
dismal,
we
also
challenges
successful
therapeutic
biomarker
development.
Oncotarget,
Год журнала:
2016,
Номер
7(22), С. 33440 - 33450
Опубликована: Март 7, 2016
//
Xiaoman
Li
1,*
,
Changjing
Wu
Nianci
Chen
2
Huadi
Gu
3
Allen
Yen
4
Liu
Cao
1
Enhua
Wang
3,5
and
Liang
Key
Laboratory
of
Medical
Cell
Biology,
Ministry
Education,
China
University,
Shenyang,
Class
9
the
97th
Clinical
Medicine
Seven-Year
Program,
Department
Pathology,
The
College
Basic
Sciences,
School
Medicine,
University
Texas
Southwestern
Center,
Dallas,
Texas,
United
States
America
5
First
Affiliated
Hospital
*
These
authors
have
contributed
equally
to
this
work
Correspondence
to:
Wang,
email:
Keywords
:
glioblastoma,
EGFR,
PI3K/Akt/mTOR
pathway,
targeted
therapy
Received
December
05,
2015
Accepted
February
24,
2016
Published
March
07,
Abstract
Glioblastoma
multiform
(GBM)
is
most
common
malignant
glioma
all
brain
tumors
currently
effective
treatment
options
are
still
lacking.
GBM
frequently
accompanied
with
overexpression
and/or
mutation
epidermal
growth
factor
receptor
(EGFR),
which
subsequently
leads
activation
many
downstream
signal
pathways
such
as
phosphatidylinositol
3-kinase
(PI3K)/Akt/rapamycin-sensitive
mTOR-complex
(mTOR)
pathway.
Here
we
explored
reason
why
inhibition
pathway
may
serve
a
compelling
therapeutic
target
for
disease,
provided
an
update
data
EFGR
inhibitors
in
clinical
trials.